Pfizer (Italy)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Azienda Ospedaliero-Universitaria Careggi意大利4
2. University of Naples Federico II意大利4
3. Ospedale Misericordia e Dolce意大利4
4. Istituto Neurologico Mediterraneo意大利4
5. Bambino Gesù Children's Hospital意大利4
6. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani意大利4
7. Uppsala Monitoring Centre瑞典2
8. University of Rome Tor Vergata意大利2

按月发文

逐年被引

最新文献

1. 1
   MAGLIO study: epidemiological analysis on invasive meningococcal disease in Italy: focus on hospitalization from 2015 to 2019—replyInternal and Emergency Medicine20240
2. 2
   MAGLIO study: epideMiological Analysis on invasive meninGococcaL disease in Italy: fOcus on hospitalization from 2015 to 2019Internal and Emergency Medicine20232
3. 3
   Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of PharmacovigilanceDrug Safety202311
4. 4
   Drug Safety in Geriatric Patients: Current Status and Proposed Way ForwardDrug Safety202012
5. 5
   The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature ReviewDrug Safety201836
6. 6
   Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety201671
7. 7
   Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritisExpert Opinion on Drug Safety201623
8. 8
   Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative reviewExpert Opinion on Drug Safety201617
9. 9
   Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety2016308

高被引文献

1. 1
   Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety2016308
2. 2
   Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety201671
3. 3
   The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature ReviewDrug Safety201836
4. 4
   Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritisExpert Opinion on Drug Safety201623
5. 5
   Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative reviewExpert Opinion on Drug Safety201617
6. 6
   Drug Safety in Geriatric Patients: Current Status and Proposed Way ForwardDrug Safety202012
7. 7
   Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of PharmacovigilanceDrug Safety202311
8. 8
   MAGLIO study: epideMiological Analysis on invasive meninGococcaL disease in Italy: fOcus on hospitalization from 2015 to 2019Internal and Emergency Medicine20232

主要发表期刊